Abcam Share Discussion Threads

[bulltradept] 05/2/2020 17:05

Fair point.

[bulltradept] 05/2/2020 16:22

Yes but China growth could take a hit from it, plus zero hedge are running a story about the figures being significantly higher, leaked official data. Check it out today.

[bulltradept] 05/2/2020 16:12

Catalogue revenue, representing approximately 95% of the total, grew by 11.6% in the first half on a reported basis and 9.1% on a constant currency basis, with all regions and product categories growing faster than estimated underlying market growth rates. Revenue in China grew faster than market at 17.4% in the year on a constant currency basis, representing over 17% of total company sales.

[bulltradept] 05/2/2020 16:09

None known China? Don't they produce over there, or markets etc?

[bulltradept] 05/2/2020 13:54

Use the ignore button, a lot have.

[bathcoup] 11/1/2020 08:50

Can't you post a summary too? Stop doing silly things!

[apad] 10/1/2020 08:19

I have to be careful about confirmation bias as I have sold a lot of ABC.
Revenue "11.6% in the first half on a reported basis and 9.1% on a constant currency basis,"
Removing China (growth of 17.4%) I calculate ROW growth of 9.4% This would be 7.4% on a constant currency basis.
Gross margin constant - 'adjusted operating profit margin' lower end of 25% - 28%. Doesn't say what the adjustment is and doesn't consider the continuing capital expenditure or comment on profit.
Two acquisitions are expected to contribute approximately £4m of incremental revenue in the current fiscal year (FY2020) and be neutral to adjusted earnings. ""We have recently set out ambitious plans to double the scale of our business and we are making good progress in investing in, and scaling up, the company."

So, big ambitions and ex growth but spending money like water and not saying anything about profit.

apad

[lenzcrafter] 10/1/2020 08:03

Watch this bomb today!

[lenzcrafter] 18/12/2019 16:11

Should have had a nibble this morning! Doh

[slogsweep] 18/12/2019 08:24

announcement - but I cant find it

[lenzcrafter] 18/12/2019 08:14

Why the huge drop??

[sunningdale1] 16/12/2019 11:01

Following on from my previous Open Orphans (ORPH) post, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform.

At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020

[lenzcrafter] 15/11/2019 21:21

A beautiful day, nice and blue.

[sunningdale1] 15/11/2019 15:40

For those interested in my previous post, big news this week from Open Orphan! Venn Life Sciences, which is part of the ORPH group has been selected as the preferred partner for pharma heavy weights Ipsen Group’s ( Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. Ipsen had sales in excess of €2.2 billion last year.

This partnership has already delivered substantial revenues for the Open Orphan group and positions the business as an integrated drug development partner for Biopharma companies in Europe such as Ipsen.

This partnership is the first of many steps to make Venn profitable and deliver a re-rating of the business to be in line with the wider sector.

CEO Cathal Friel summaries the significance of the agreement in 2 minute video below.

[ifthecapfits] 29/10/2019 11:08

I guess not.

[mayers] 04/10/2019 20:46

Sunningdale. Would you be able to explain the implications of ORPH for Abcam? Thanks.